KRSNAA Krsnaa Diagnostics Q1 FY27 results (Apr–Jun 2026) and concall
Management summary
- Krsnaa Diagnostics reported a strong 22% YoY revenue growth in Q1 FY27.
- The ramp-up of the Rajasthan PPP project and robust 64% growth in its retail segment..
- However, profitability was impacted by upfront costs for new project implementations, leading to EBITDA margin compression to 25%.
- Management expects margins to improve and the retail segment to become EBITDA positive by Q2 FY27 as projects mature and utilization increases.
Source: Inve concall analysis and management guidance record.
Highlights
-
Revenue from operations for Q1 FY27 stood at INR 2,355 million, representing a 22% year-on-year growth.
-
Retail revenue for Q1 FY27 grew at an impressive 64% year-on-year to INR 193 million, contributing approximately 9% of overall group revenue.
-
Krsnaa was awarded the Himachal Pradesh CT project for 34 CT scans, expanding its footprint in the state from 12 to 34 centers, with this project predominantly being cash-paying.
-
The Rajasthan project has moved decisively from the implementation phase into the go-live and operational phase, with 31 Mother labs, 62 hub labs, and 1,228 collection centers now operational.
What they filed
Q1 FY27: revenue up 150.0%, net profit down 20.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 9 | 10 | 8 | 2 | -3 −133% | -1 −110% | 20 +150% |
| EBITDA | 48 | 53 | 50 | 58 | 48 +0% | 57 +8% | 57 +14% |
| Net profit | 22 | 21 | 20 | 23 | 16 −27% | 43 +105% | 16 −20% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Rajasthan PPP Revenue Revenue · full year FY27 · Medium confidence INR 100-150 crores
Previously INR 200-250 crores → INR 100-150 crores
Rajasthan PPP Revenue Growth Revenue · coming quarters · High confidence double up
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Increase in fee to hospitals Direct
So actually, the -- whilst the accounting nomenclature is fees to hospital, this is also - the actual increase is on account of Rajasthan project. So for a project like Rajasthan or even other PPP projects, we have certain partners that we work in these remote locations. And ther
Explains a significant increase in 'fees to hospital' expense (INR 41 crores) as revenue sharing with partners for large-scale projects like Rajasthan, rather than a direct hospital fee.
Asked by Raman from Sequent Investments
Rajasthan PPP revenue guidance for FY27 Partial
Rajasthan revenue, I think we have reported around INR26 crores. And from an annualized basis, I think even if you just multiply this by 4, what number we are expecting is about INR100 crores to INR150 crores of Rajasthan for the full year. ... And it will grow. I mean since this
Clarifies the current contribution of Rajasthan PPP and provides a more conservative full-year revenue guidance (INR 100-150 crores) compared to previous aspirations, with expectations for significant ramp-up in coming quarters.
Asked by Raman from Sequent Investments
Unlock risks & concerns, Q2 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 5 risks, concerns & management red flags
- 5 watchlist triggers for Q2 FY27
- +6 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





